Allergan recently announced it plans to acquire ForSight VISION5 — a privately-held, clinical-stage biotechnology company focused on eye care.
Under terms of the agreement, Allergan will reportedly acquire ForSight's lead product, which is a peri-ocular ring designed for extended drug delivery and reducing elevated intraocular pressure (IOP) in glaucoma patients. According to Allergan, the non-invasive ring can be inserted by an ophthalmologist or optometrist — it rests on the surface of the eye and releases bimatoprost over multiple months to lower elevated IOP in glaucoma and ocular hypertensive patients.
Click here to read the full press release.